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Introduction
Platelets are the guardians of hemostasis, but are also
established mediators of pathological thrombosis causing
myocardial infarction and stroke. More recently, novel
unconventional roles for platelets have emerged with
the repertoire extending to numerous physiological and
pathological roles within the body. From a physiological
context, platelets are crucial for tissue regeneration,1
wound healing,2 and protecting from septic shock,3 but
pathologically, they have established roles in atherogen-
esis,4 tumor stability,5 and metastasis.6 Key to this func-
tional heterogeneity is the armory of biological cargo
stored within distinct secretory platelet granules, namely,
α-, dense, and lysosomal granules, the contents of which
are released upon platelet activation. Platelet α-granules
represent the most abundant and heterogeneous granules
in terms of cargo, containing over 300 proteins released
upon activation.7 These include growth factors, chemo-
kines, cytokines, clotting factors, and adhesive proteins,
and are widely recognized for eliciting this broad func-
tionality of platelets.8,9
In this study, we assessed the direct effects of released
cargo from activated platelets on isolated ventricular cardi-
omyocytes during ischemic injury. Undoubtedly, platelets,
through occlusive thrombosis of coronary arteries, trigger
ischemic injury and furthermore they have causative roles in
the pathogenesis of myocardial reperfusion injury, particu-
larly through their ability to recruit and activate inﬂamma-
tory cells.10,11 Interestingly, cardioprotective roles for
platelets have also been described, effects which appear to
be indirectly mediated by the endothelium.12,13 However,
there is no evidence assessing direct, paracrine effects of
platelet-derived factors on cardiomyocytes during ischemic
injury. Recently, heterocellular signaling pathways between
endothelial-derived growth factors (neuregulin-1) and
ErbB4 receptors on cardiomyocytes have been identiﬁed
and we therefore hypothesized that vascular endothelial
denudation, which initiates platelet activation, represents
a likely conduit for soluble platelet-derived factors to interact
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Abstract Platelets are classically known for their roles in bleeding control and occlusive
thrombus formation causing ischemic tissue damage. Recently, nonclassical roles
for platelets have been described, many of which may be mediated by the hetero-
geneous cargo that platelets secrete from granular stores upon activation. Using an in
vitro model of ischemic injury to ventricular cardiomyocytes, we observed that
platelets, through secreted factors, delayed the rate of cardiomyocyte death during
ischemia. This protective effect appeared independent of platelet dense granule cargo,
but required α-granule components stromal cell-derived factor-1α and transforming
growth factor-β1. Protein kinase C activity within cardiomyocytes was responsible for
mediating the protective signals initiated by the released platelet cargo. Importantly,
pretreating platelets with a P2Y12 antagonist, but not the cyclooxygenase inhibitor
aspirin, substantially attenuated this protective effect. These ﬁndings therefore reveal a
paradoxically protective role for platelet activation during cardiac ischemia and could
have important implications for the use of antiplatelet therapeutics in the manage-
ment of myocardial infarction.
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with the myocardium directly during coronary thrombo-
sis.14 Our study identiﬁes a novel role for platelets in pre-
conditioning cardiomyocytes to ischemic damage. We show
that secreted platelet factors alter the tolerance of cardio-
myocytes to ischemic injury by delaying the rate of cardio-
myocyte death and we further explore the mechanism
behind this protective effect. Importantly, we observed
that blocking platelet P2Y12, a clinical target of platelet-
dependent thrombosis, obscures this nonconventional
aspect of platelet function. This is in contrast to aspirin,
also used clinically in the management of myocardial infarc-
tion, which preserves the cardioprotective effects of platelets
and could therefore have future implications for antiplatelet
strategies in the management of heart attacks.
Methods
Mice
All animal studies were approved by the local research ethics
committee at the University of Bristol. Mice were bred and
maintained in the University of Bristol animal facility in
accordance with the UK Home Ofﬁce regulations and Ani-
mals (Scientiﬁc Procedures) Act of 1986 (PPL No: 3003445).
Male, C57BL/6 wild-type (WT) mice were from Harlan
Laboratories (Bicester, UK). Unc13dJinx mice on a C57BL/6
backgroundwere from theMutant Mouse Regional Resource
Center (University of California, United States).
Platelet Preparation
Eight- to 20-week old mice were sacriﬁced by a gradual rise in
CO2 and blood was drawn from the inferior vena cava into a
syringe containing 4% trisodium citrate (1:10 v/v). Washed
platelets were prepared as previously described,15 resus-
pended in modiﬁed HEPES-Tyrode’s buffer (10 mM HEPES,
145mMNaCl, 1 mMMgCl2, 3 mMKCL, 5 mMGlucose, pH 7.3)
withoutapyraseadditionandallowedto recover for30minutes
at 30°C. Immediately prior to stimulation, 1 mM CaCl2 was
added to platelets.
Platelet Activation: Releasate Isolation and α-Granule
Secretion
For platelet experiments involving pharmacological inhibitors,
plateletsat2  108/mLwerepretreated for10minutesprior to
stimulation with vehicle (HEPES-Tyrode’s) or 10 µg/mL
collagen-related peptide (CRP; from Prof. Richard Farndale,
University of Cambridge, UK) for 15minutes at 37°C. Inhibitors
AR-C 66096 (Tocris Bioscience, Bristol, UK) and aspirin (Sigma-
Aldrich, Poole, UK) were used to block P2Y12 and cyclooxy-
genase, respectively. For releasate isolation, 140 nmol/L PGE1
(Sigma-Aldrich)wasaddedpoststimulation andplateletswere
pelleted by centrifugation at 580g for 10 minutes. The super-
natant containing released platelet factors (henceforth
referred to as “platelet releasate”) was removed and subjected
to 2 pulse centrifugations to clarify any remainingdebris and
the soluble releasate was used to pretreat cardiomyocytes.
Fractionation of the platelet releasates using 3-kDa molecular
weight cutoff ﬁlters was performed as per manufacturer’s
instructions (Millipore, Hertfordshire, UK). In brief, 500 µL of
platelet releasate was centrifuged at 14,000g for 20 minutes.
This yielded approximately 400 µL of ﬁltered releasate, with
approximately 100 µL of retained releasate, which was ad-
justed to 400 µL with HEPES-Tyrode’s. To measure α-granule
secretion, platelets, poststimulation, were incubated with
2.5 µL FITC-labeled antimouseCD62P (Emfret Analytics,Würz-
burg, Germany) for 5 minutes, then ﬁxed in 1% paraformalde-
hyde for 30 minutes and analyzed using a FACS Canto II ﬂow
cytometer (Becton Dickenson, New Jersey, United States).
Samples were analyzed with FACSDiva software where a total
of 10,000 gated events per sample were collected.
Ventricular Cardiomyocyte Isolation
Male, adult (9–14 weeks) WT mice were intraperitoneally
injected with 400 U of heparin prior to schedule 1 by
cervical dislocation. Hearts were rapidly excised and placed
in a nominally (0.05 mM) CaCl2-free HEPES-Tyrode’s perfu-
sion buffer (henceforth referred to as perfusion buffer—
130 mM NaCl, 5.4 mM KCL, 0.4 mM NaH2PO4, 4.2 mM
HEPES, 10 mM Glucose, 1.4 mM MgCl2, 20 mM Taurine,
1 mM Creatine, 10 mM 2,3-butanedione monoxime, and pH
7.4). The aorta was cannulated and the heart perfused
retrograde, in a noncirculating mode on a Langendorff
apparatus in CaCl2-free perfusion buffer at a ﬂow rate of
3 mL/min for 4 minutes at 37°C. The buffer was switched to
a myocyte digestion buffer containing 0.7 mg/mL collage-
nase type II (Worthington Biochemicals, New Jersey, United
States) and 0.1 mg/mL Protease XIV (Sigma-Aldrich) in
0.05 mM CaCl2-containing perfusion buffer for 15 minutes
at 37°C until the heart appeared pale and swollen. Atria
were removed and digested ventricles were minced and
triturated in perfusion buffer containing 5% fetal calf serum
to inactivate proteases, and then sequentially ﬁltered
through a 200-µm nylon gauze (Millipore) resulting in
four isolates. Cardiomyocytes were isolated by centrifuga-
tion for 1 minute at 60g, resuspended in 0.1 mM CaCl2
containing perfusion buffer, and visualized at 100 on a
light microscope (Swift M4000-D, California, United
States). Isolate 1 contained mostly round, hypercontracted
and nonviable cardiomyocytes which were discarded. Iso-
lates 2 to 4 were pooled and Ca2þwas gradually restored in
a step-wise fashion to 1 mM over 30 minutes. The isolation
typically yielded 60% Ca2þ tolerant cardiomyocytes.
In vitro Myocardial Ischemia Viability Assay
The assay setup was based on the established “ischemic
pelleting” model, with minor modiﬁcations.16 For experi-
ments involving pharmacological inhibitors, cardiomyocytes
were pretreated for 30 minutes with indicated inhibitors:
AMD3100 (CXCR4); SB431542 (TGFBR1), and BIM I (protein
kinase C [PKC])—all from Tocris. Cardiomyocytes were then
treated with platelet releasates, diluted 1:2 with 1 mM Ca2þ
containing perfusion buffer or recombinant proteins for
10 minutes at 37°C. Cardiomyocytes were then allowed to
recover for 10 minutes in perfusion buffer prior to ischemic
pelleting.With the cardiomyocytes pelleted, precisely 450 µL
buffer was removed from each sample, which was
carefully layered with 200 µL mineral oil to exclude gaseous
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exchange and initiate ischemia, that is, T ¼ 0 minutes. Every
30 minutes (for up to 240 minutes), a 2.5 µL sample was
removed from the pellet and resuspended in 50 µL reperfu-
sion buffer (perfusion buffer containing 3 mM Amytal –
Sigma-Aldrich) for 4 minutes. The sample was mixed with
an equal volume of counting media (perfusion buffer con-
taining 1% glutaraldehyde and 0.4% trypan blue) allowing
detection of viable (trypan blue excluded) and nonviable
(trypan blue stained) cardiomyocytes. Images were acquired
with a mounted digital microscope camera (AmScope,
California, United States) at 100 magniﬁcation, with eight
random ﬁelds of view per sample at every time point
(equating to  250–300 cardiomyocytes/time point). This
method allowed for amaximum of three treated samples per
isolation.
Western Blotting
Cardiomyocytes were lysed in buffer (150 mM NaCl, 20 mM
Tris, pH 7.4, 1 mM EDTA, 1% Triton X-100) containing
protease and phosphatase inhibitor cocktail sets (Roche,
UK) and harvested as previously described.17 Equal amounts
of protein (15 µg/sample) were resolved by electrophoresis
on 10% Tris-glycine gels, transferred onto Immobolin PVDF
membranes (Millipore), blocked and probed with speciﬁc
antibodies: Phospho-(Ser) PKC substrate, phospho-Erk1/2,
(Thr202/Tyr204), Erk1/2, phospho-Akt, (Ser 473), and Akt
antibodies (all 1:1,000 dilution) were from Cell Signaling
Technology (Massachusetts, United States) and mouse–anti-
GAPDH (1:2,000 dilution) was from Santa Cruz Biotechnol-
ogy (Heidelberg, Germany). HRP-conjugated secondary anti-
bodies (antimouse and antirabbit, both 1:10,000 dilution)
were from GE Healthcare (Buckinghamshire, UK).
Statistical Analysis
All data were analyzed using GraphPad Prism 7 software
(GraphPad Software Inc., California, United States). Data are
presented as mean  standard deviation with the indicated
number of independent experiments. Statistical analysis was
determined using one- or two-way ANOVA with Bonferroni’s
post hoc test. p < 0.05was considered statistically signiﬁcant.
Results
Released Factors from Platelet Granules Protect
Cardiomyocytes during Ischemia
During myocardial infarction, platelets release bioactive
molecules exerting autocrine/paracrine effects causing oc-
clusive thrombosis of coronary arteries, with subsequent
ischemic damage to cardiac tissue.18 Our initial observations
demonstrated that biomolecules released from platelets
activatedwith 10 µg/mL CRP, a ligand for the platelet-speciﬁc
collagen receptor, glycoprotein (GP) VI, could delay the rate
of cardiomyocyte death during ischemic injury compared
with controls (►Fig. 1A, B). The effect was not immediate,
but was consistently observed between 60 and 180 minutes
post ischemia onset and lost between 210 and 240 minutes.
Dose response analysis identiﬁed 10 µg/mL CRP to induce
maximal platelet secretion, by means of surface exposure of
the α-granule protein, CD62P (►Fig. S1A, supplementary
ﬁgure available in the online version only). Importantly,
control experiments with CRP alone did not alter the cardi-
omyocyte response to ischemic cell death (►Fig. S1B, sup-
plementary ﬁgure available in the online version only).
Platelet granules represent the most abundant sources for
released platelet cargo and Unc13djinx mice, which lack the
Fig. 1 Factors released from platelet secretory vesicles protect cardiomyocytes from ischemic injury. (A and D) Cardiomyocytes from wild-type
(WT) hearts preconditioned with released factors from vehicle-treated (control) and collagen-related peptide (CRP)-treated (stimulated)
platelets fromWTor Unc13dJinx mice (as indicated) were subjected to ischemic injury using a cell pelleting method. Samples from the pellet were
analyzed for cell viability every 30 minutes, for up to 240 minutes, with nonischemic (oxygenated control) samples monitored at 0- and 240-
minute time points. Data are mean  SD (n ¼ 7 for (A), n ¼ 5 for (D)), (A) p < 0.05, p < 0.001 versus WT-controlled releasate and (D)
ΦΦp < 0.01, ΦΦΦp < 0.001 versus Unc13dJinx stimulated releasate. (B) Representative images of trypan blue stained and nonstained
cardiomyocytes at 60-minute intervals throughout ischemia assay (0–240 minutes). (C) Washed platelets (2  108/mL) from WT and Unc13dJinx
mice were treated with vehicle control (Tyrode’s) or 10 µg/mL CRP and monitored for α-granule secretion by CD62P surface expression. Data are
mean  SD; n ¼ 3, p < 0.01. Two-way ANOVA with Bonferroni post hoc test for (A), (C), and (D).
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vesicle priming protein Munc13–4, have proved useful in
dissecting functional roles for platelet granules.19 We con-
ﬁrmed platelet α-granule secretionwith CRP was reduced by
approximately 82% in Munc13–4/ platelets (►Fig. 1C).
Subsequent experiments demonstrated that the cardiopro-
tective effects of stimulated platelet releasates from these
mice were completely lost in comparison to wild-type (WT)
stimulated platelet releasates, suggesting the active compo-
nent(s) in the releasate are of granular origin (►Fig. 1D).
Platelet Dense Granules Are Not the Source of
Cardioprotective Cargo
To discriminate between dense and α-granule cargo, we took
advantage of the fact that cargo in dense granules has
generally very low molecular mass, whereas that in
α-granules is principally peptide based and is ofmuch higher
average molecular mass. We therefore fractionated the sti-
mulated releasates fromWTplatelets into less than andmore
than 3 kDa fractions. Notably, the less than 3 kDa fraction did
not delay the kinetics of cardiomyocyte death during ische-
mia, whereas the more than 3 kDa fraction did signiﬁcantly
delay cardiomyocyte death in a manner similar to unﬁltered
releasates from stimulatedWTplatelets (►Fig. 2A). To ensure
the fractionation procedure effectively separated dense and
α-granule components, we demonstrated that a signiﬁcant
portion ( 78%) of released adenosine triphosphate (ATP) is
present in the less than 3 kDa fraction (►Fig. S2A, supple-
mentary ﬁgure available in the online version only). These
data support the hypothesis that α-granule content, but not
dense granule content, mediates the cardioprotective effect.
Fig. 2 Role for platelet α-granule proteins, SDF-1α and TGF-β1, in mediating the protective effects of platelet secreted factors. (A–F)
Cardiomyocytes were preconditioned with releasates from vehicle-treated (control) WT platelets: (A) ﬁltered, <3 kDa and retained, >3 kDa
releasates from CRP-treated (stimulated) WT platelets; (B) recombinant SDF-1α (100 ng/mL); (C) recombinant TGF-β1 (100 ng/mL) and (D–F)
unﬁltered releasate from CRP-treated (stimulated) WT platelets, then monitored for cardiomyocyte viability for up to 240 minutes of ischemic
injury, with nonischemic (oxygenated control) samples monitored at 0- and 240-minute time points. (D–F) Cardiomyocytes were pretreated with
vehicle control (0.1% DMSO) or inhibitors: (D) 0.5 µM AMD3100 (CXCR4 antagonist); (E) 1 µM SB431542 (TGFBR1 antagonist), and (F) 0.5 µM
AMD3100 and 1 µM SB431542 for 30 minutes prior to releasate preconditioning. Data are mean  SD (n ¼ 4 for (A) and (F), n ¼ 3 for B–E);
p < 0.05, p < 0.01, p < 0.001 versus control releasate (A, D–F)/vehicle (B,C) and Φp < 0.05, ΦΦp < 0.01, ΦΦΦp < 0.001 versus stimulated
releasate (<3 kDa (A)/ þ AMD3100 (D)/ þ SB431542 (E)/AMD3100 þ SB431542 (F)).
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Cardioprotective Roles for Platelet α-Granule Proteins
SDF-1α and TGF-β1
Platelet α-granules are loadedwith functionally active proteins,
some of which have been previously implicated as having
protective effects on cardiac tissue, including the cytokines
stromal cell-derived factor (SDF)-1α and transforming growth
factor (TGF)-β1.20,21 Initially, we demonstrated that recombi-
nant SDF-1α or TGF-β1 could signiﬁcantly delay cardiomyocyte
death during ischemia compared with vehicle-treated cardio-
myocytes (►Fig. 2B, C). Subsequently, we assessed the func-
tional relevance of platelet-derived SDF-1α and TGF-β1 by
targeting their respective receptors, CXCR4 and TGFßR1, both
of which are expressed on cardiomyocytes.22,23 Blocking CXCR4
with AMD3100 or TGFßR1 with SB431542 on cardiomyocytes
caused a subtle, yet signiﬁcant reversal of the cardioprotective
effect of the stimulated platelet releasate between 60 and
120 minutes of ischemia (►Fig. 2D, E). However, blocking
both receptors simultaneouslycausedamoreprofoundattenua-
tion of the protective effect and persisted from 60 up to
180 minutes of ischemia, at which point the protective effect
typically dissipates (►Fig. 2F). Control experiments with
AMD3100 or SB41542 did not reveal any baseline effects on
cardiomyocyte viability during ischemia when compared with
vehicle-treated cardiomyocytes (data not shown).
Protein Kinase C Is Essential for Platelet Releasate-
Mediated Cardioprotection
Considering the protective effects of the stimulated platelet
releasates, we sought to determine possible prosurvival
signaling mechanisms activated within cardiomyocytes
during ischemia. By measuring serine phosphorylated PKC
substrates, we observed that stimulated platelet releasates
enhanced PKC activity between 30 and 120 minutes of
ischemia relative to control releasate-treated cardiomyo-
cytes (►Fig. 3A). However, we did not detect any temporal
differences in the phosphorylation kinetics of the kinases,
Akt or Erk 1/2 between treatments (►Fig. 3A). To assess a
potentially causal role for PKC, pretreatment of cardiomyo-
cytes with a pan PKC inhibitor, BIM I, completely suppressed
the cardioprotective response of the stimulated platelet
releasate during ischemia (►Fig. 3B). Control experiments
with BIM I alone treated cardiomyocytes conﬁrmed that PKC
inhibition does not induce a baseline reduction in cardio-
myocyte viability during ischemia, relative to vehicle-treated
cardiomyocytes (►Fig. S4, supplementary ﬁgure available in
the online version only).
Clinical Antiplatelet Target P2Y12, but Not
cyclooxygenase-1, Is Important for Cardioprotective
Effects of Platelets
Clinically, a mainstay of therapy for myocardial infarction is
the rapid control of platelet function to prevent further
thrombotic and ischemic episodes and to help destabilize
any ongoing thrombotic event. Antiplatelet therapies target
the activatory adenosine diphosphate (ADP) and thrombox-
ane A2 ampliﬁcation pathways in platelets by blocking the
P2Y12 receptor, via clopidogrel and cyclooxygenase (COX)-1,
via low-dose aspirin, respectively. Under our conditions,
Fig. 3 Protein kinase C (PKC) activity is essential for platelet releasate-mediated cardioprotection. (A) Cardiomyocytes preconditioned with
releasates from vehicle- (control) and CRP- (stimulated) treated WT platelets were subjected to ischemic injury, with samples removed from the
pellet and lysed at indicated ischemic time points. Samples were monitored for changes in PKC activity (Phospho serine PKC substrate), phospho
Akt (Ser473), and Erk 1/2 (Thr202/Tyr204) by immunoblotting with speciﬁc antibodies followed by appropriate loading controls. Blots shown are
representative of three independent experiments. (B) Cardiomyocytes were pretreated in the absence (þ DMSO vehicle) or presence of 10 µM
BIM I for 30 minutes prior to preconditioning with releasates from vehicle- (control) and CRP-treated (stimulated) WT platelets, then monitored
for cardiomyocyte viability for up to 240 minutes of ischemic injury, with nonischemic (oxygenated control) samples monitored at 0- and 240-
minute time points. Data are mean  SD; n ¼ 4, p < 0.05, p < 0.01, p < 0.001 versus control releasate, ΦΦp < 0.01, ΦΦΦp < 0.001 versus
stimulated releasate (þ BIM I). Two-way ANOVA with Bonferroni post hoc test.
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pretreating platelets with the P2Y12 inhibitor, AR-C 66096,
reduced CRP-induced α-granule secretion by approximately
51%, whereas aspirin had no signiﬁcant effect (►Fig. 4A).
Consistent with the effect on α-granule secretion, blockade
of P2Y12 in platelets, alone or in combination with aspirin,
substantially attenuated the subsequent protective effect of
the stimulated releasate on cardiomyocyte viability during
ischemia (►Fig. 4C, D), whereas stimulated releasates from
aspirin alone pretreated platelets did not exhibit a signiﬁcant
reduction in cardioprotection compared with stimulated
releasates from vehicle-treated platelets (►Fig. 4B).
Discussion
Platelets play a critical role in the pathogenesis ofmyocardial
infarction, initiating the ischemic damage through the
thrombotic plug that they form in the coronary vessels. As
part of their activity, however, platelets secrete cargo that is
able to exert localized effects on numerous cells at the injury
site, including leukocytes and endothelial cells.24,25Here, we
hypothesized that through secretion of multiple bioactive
mediators platelets may play a paradoxical protective role in
addition to their induction of ischemic damage. This study
reveals new paracrine signaling capabilities of platelets to
modulate the sensitivity of myocardial cardiomyocytes to
ischemic injury.
It iswell described that themyocardiumpossesses its own
inherent, cardioprotective capacity as short bouts of ische-
mia, followed by reperfusion, and can protect cardiomyo-
cytes from prolonged exposure to ischemia, a phenomenon
referred to as ischemic preconditioning (IPC).26 Importantly,
the isolated in vitro model used in this study, which was ﬁrst
described by Vander Heide et al, has been effectively utilized
to recapture the IPC effect observed from various in vivo and
ex vivo models.16,27 Our observations that released cargo
from platelets stimulated with maximal doses of CRP could
temporally delay the kinetics of cardiomyocyte death are
consistent with the responses observed from earlier studies
demonstrating the protective effects of acute IPC.27,28 In-
evitably, absolute protection of cardiomyocytes is not sus-
tained with prolonged ischemia and this acute protective
effect is lost by 240 minutes of ischemia. Importantly, the
receptor for CRP, GPVI, has established roles in platelet-
mediated coronary thrombosis, but is also platelet-speciﬁc,
allowing for discrimination against any potential “off-target”
effects on cardiomyocytes that other common platelet ago-
nists such as thrombin, ADP, and thromboxane A2 may incur.
To explore the most probable candidate sources of bio-
molecules within the platelet releasate, we utilized platelets
from Unc13dJinx mice, which are unable to secrete dense
granule cargo and have severely compromised α-granule
(►Fig. 1C) and lysosomal cargo release.29 Notably, CRP-
stimulated platelet releasates from these mice completely
lost the protective effect on cardiomyocyte viability during
ischemia compared with WT platelets. Dense granules are
loaded with high concentrations of low-molecular-weight
components, in particular adenine nucleotides (ADP and
ATP), divalent cations (Ca2þ, Mg2þ), and neurotransmitters
(serotonin, histamine) and are critical regulators of throm-
bosis and vascular remodeling.30 Separating these compo-
nents from larger α-granule cargo by fractionation showed
that the dense granule content was incapable of supporting
cardioprotection. Interestingly, adenosine has previously
been shown to have a cardioprotective effect and could be
formed by degradation of secreted ADP and ATP by platelet
surface ectonucleotidases, CD39 and CD73.31 However, pre-
conditioning cardiomyocytes with adenosine did not signif-
icantly delay the rate of cardiomyocyte death, providing
Fig. 4 Targeting platelet P2Y12, but not cyclooxygenase, reduces platelet secretion and cardioprotection. (A) Washed platelets (2  108/mL)
fromWTmice were pretreated with vehicle (Tyrode’s) or inhibitors; 30 µM aspirin (cyclooxygenase) and 1 µM AR-C 66096 (P2Y12 antagonist) for
10 minutes, then stimulated with 10 µg/mL CRP and analyzed for α-granule secretion by surface CD62P exposure. Data are mean  SD; n ¼ 4,
p < 0.001, one-way ANOVA with Bonferroni post hoc test. (B–D) Cardiomyocytes preconditioned with releasates from vehicle-treated
(control) or CRP-treated (stimulated) WT platelets in the absence (þ Tyrode’s vehicle) or presence of (B) 30 µM aspirin, (C) 1 µM AR-C 66096, and
(D) 30 µM aspirin þ 1 µM AR-C 66096 were monitored for changes in viability during ischemic injury, with nonischemic (oxygenated control)
samples monitored at 0 and 240 minutes time points. Data are mean  SD; n ¼ 4, p < 0.05, p < 0.01, p < 0.001 versus WT-controlled
releasate (þ vehicle (B–D)) and Φp < 0.05, ΦΦp < 0.01, ΦΦΦp < 0.001 versus stimulated releasate (þAspirin (B)/ þ ARC66096 (C)/
þ Aspirin þ AR-C66096 (D)), two-way ANOVA with Bonferroni post hoc test.
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further supportive evidence for dense granule cargo lacking a
cardioprotective role in our model (►Fig. S2B, supplemen-
tary ﬁgure available in the online version only).
Platelet lysosomal number is low and their cargo, which
contains numerous proteases implicated in vessel remodel-
ing post injury, makes it an unlikely source of cardioprotec-
tive factors. Conversely, platelet α-granules, of which there
are approximately 50 to 80 per platelet, are loaded with
functionally active cargo with the ability to target numerous
vascular cells.32 Pertinent to our ﬁndings, the α-granule
proteins, SDF-1α and TGF-β1, both of which are known to
be secreted from activated platelets,33 have also been im-
plicated in cardioprotection. We observed that pretreating
cardiomyocytes with recombinant SDF-1α or TGF-β1 could
substantially delay the rate of cardiomyocyte death during
ischemia, in a manner similar to stimulated platelet relea-
sates, but individually blocking the respective receptors for
these ligands, CXCR4 and TGFßR1, could only partially block
the cardioprotective effect of the releasate. Importantly, the
dose of the receptor antagonist was sufﬁcient to completely
block the effect of their respective recombinant ligand
(►Fig. S3A, B, supplementary ﬁgure available in the online
version only). The apparent discrepancy between ﬁndings
with the platelet releasate and recombinant pretreatments
likely reﬂects differences in soluble ligand concentration
between the two, but may also reﬂect the opposing, func-
tional nature of different components of the complex se-
creted platelet cargo.34 Interestingly, simultaneous blockade
of CXCR4 and TGFßR1 caused a more substantial attenuation
in platelet releasate-mediated cardioprotection, suggesting a
synergistic or additive contribution of different cargo to the
protective effect. However, the attenuation was not com-
plete, implicating other secreted platelet granule contents,
possibly additional α-granule peptide(s), as additive or sy-
nergistic regulators in this complex releasate. Indeed, syner-
gistic behavior of various growth factors toward scavenger
receptor activity in smooth muscle cells has been previously
reported andwe speculate that a similarmodality of function
may be in effect here.35
Mechanistically, we wanted to explore possible prosurvi-
val targets within cardiomyocytes that were sensitive to
releasate stimulation. The kinases Akt and Erk1/2 have
been previously linked to cardioprotection, but we did not
detect any temporal differences in phosphorylation kinetics
between vehicle- and CRP-stimulated platelet releasates
during ischemia.36,37 However, we did detect prolonged
PKC activity during ischemia in the stimulated releasate
samples. Pertinent to this, the PKC family is widely recog-
nized for its regulatory roles in IPC,38,39 and previous studies
have also identiﬁed signaling links between either SDF-1α or
TGF-β1 and PKC.40,41 Findings from our functional ischemia
assay suggest that PKC signaling within cardiomyocytes is
essential to the protective effect of the releasate. The end
effectors that functionally couple PKC activity to a cardio-
protective response are still not determined. Some evidence
suggests that PKC activity increases opening of the mito-
chondrial and sarcolemmal ATP-dependent potassium (KATP)
channels, which lowers Ca2þ loading during ischemia and
protects the mitochondrial permeability transition pore
(mPTP) from the deleterious effects of elevated Ca2þ. Other
studies, however, dispute the KATP channel theory, suggest-
ing that a lowering of oxidative stress during ischemia
desensitizes the mPTP to the deleterious effects of Ca2þ
loading.42,43
Undoubtedly, the initiating predisposition to myocardial
ischemic injury is a platelet-mediated process and antiplate-
let therapies are prophylactically administered as effective
tools in the primary and secondary prevention of occlusive
thrombosis.44 Interestingly, blockade of P2Y12, but not as-
pirin, signiﬁcantly reduced the cardioprotective effect of the
platelet releasate. Unlike stimulated releasates from
Munc13–4/ platelets, the reversal of the protective effect
with P2Y12 inhibition was not complete and likely reﬂects
the greater attenuation of platelet α-granule secretion in
Unc13dJinx mice. Consistently, aspirin treatment did not
signiﬁcantly alter α-granule secretion or cardioprotection
from the platelet releasate. Findings from in vivo studies of
myocardial ischemia-reperfusion (I/R) injury, by coronary
artery ligation, may seem to contradict our data, as different
studies have demonstrated cardioprotective effects of the
antiplatelet therapies and also implicated platelet-speciﬁc
roles during I/R injury pathogenesis.10,45,46 Interestingly,
other studies have demonstrated that the P2Y12 antagonist,
clopidogrel, had no effect onmyocardial I/R injury, despite its
antiplatelet effect, while it has also been suggested that the
cardioprotective effect of a more recently developed P2Y12
antagonist, ticagrelor, may be independent of its antiplatelet
properties.47,48 Notably, the mechanical nature of ligation in
these in vivo models, in place of occlusive thrombosis due to
endothelial disruption, raises issues concerning themechan-
ism of platelet activation and secretion, and makes accurate
inferences more challenging. The in vitro model used here is
also not without limitations, as it lacks the mechanics of
reperfusion hypercontracture from an intact myocardium
and also the inﬂuence of other vascular cells.49 It does also
presume that soluble platelet cargo can target the myocar-
dium during thrombosis. However, in light of evidence
demonstrating a functional crosstalk between endothelial
growth factors and cardiomyocytes, it is probable that such a
conduit exists during endothelial disruption and coronary
thrombosis.14 Importantly, themodel does allow us tomimic
platelet activation and secretion relevant to thrombosis,
which is currently lacking in the coronary ligation model
of myocardial infarction. Our approach therefore allowed us
to monitor cardiomyocyte viability over time during ische-
mia, and the effect of activated platelet releasates on this
viability.
Overall, our ﬁndings suggest that platelet-released factors
enhance a therapeutic window of cardiomyocyte survival
during ischemia, highlighting a double-edged sword func-
tionality of platelets because they are also causative of the
initial ischemic insult. This adds to the expanding list of
nonclassical roles for platelets, and also highlights important
considerations for antiplatelet therapies that alter platelet
activity and in particular granule secretion, as this cargo
possesses numerous beneﬁcial inﬂuences, for example, in
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the context of wound healing,50 yet deleterious conse-
quences in the context of tumor growth and stability.5 The
intriguing observation in this study is that in the context of
ischemic damage to cardiomyocytes, platelet P2Y12, but not
cyclooxygenase, blockademay block the release of protective
components from platelets. The supposition here is not to
undermine the protective capabilities of P2Y12 inhibitors in
the primary prevention of ischemic tissue damage, but to
raise important issues regarding the utility of antiplatelet
therapies that impact on nonclassical aspects of platelet
biology.
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